Literature DB >> 12224573

Anemia in parasite- and recombinant protein-immunized aotus monkeys infected with Plasmodium falciparum.

Trevor R Jones1, David F Stroncek, Alfonso S Gozalo, Nicanor Obaldia, Ellen M Andersen, Carmen Lucas, David L Narum, Alan J Magill, B K L Sim, Stephen L Hoffman.   

Abstract

Plasmodium falciparum-induced anemia was characterized in Aotus monkeys repeatedly immunized by infection with P. falciparum (FVO strain) parasites, then cross-challenged with CAMP strain, or in monkeys receiving blood stage challenges as part of malaria vaccine trials. In 4 studies, 25 (30.5%) of 82 monkeys had at least a 50% reduction in hematocrit; mean day of maximum parasitemia was 12.5, whereas the mean day of minimum hematocrit was 18.8 (P < 0.0009). Decreased hematocrit levels were not associated with reticulocytosis until parasite densities decreased significantly from peak levels. Direct antibody tests to detect IgG and C3d on the surface of erythrocytes were negative. Nonantibody/noncomplement-mediated lysis of uninfected erythrocytes seems to be the principal cause of the anemia, and it also seems that bone marrow suppression and lysis of infected erythrocytes contributed to the anemia. Partial immunity-whether induced by repeated immunization with whole parasites or with vaccine-seems important to the development of anemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224573     DOI: 10.4269/ajtmh.2002.66.672

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

Review 1.  Malaria-related anaemia: a Latin American perspective.

Authors:  Juan Pablo Quintero; André Machado Siqueira; Alberto Tobón; Silvia Blair; Alberto Moreno; Myriam Arévalo-Herrera; Marcus Vinícius Guimarães Lacerda; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria.

Authors:  Lisa H Xie; Qigui Li; Ai J Lin; Kirsten Smith; Jing Zhang; Donald S Skillman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Severe malarial anemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes.

Authors:  Krystal J Evans; Diana S Hansen; Nico van Rooijen; Lynn A Buckingham; Louis Schofield
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

4.  Sequential Plasmodium chabaudi and Plasmodium berghei infections provide a novel model of severe malarial anemia.

Authors:  Juliana V Harris; Tiffany M Bohr; Catherine Stracener; Mary E Landmesser; Vladimir Torres; Amos Mbugua; Chantal Moratz; José A Stoute
Journal:  Infect Immun       Date:  2012-06-11       Impact factor: 3.441

5.  A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge.

Authors:  Nicanor Obaldia; Michael G Stockelman; William Otero; Jennifer A Cockrill; Harini Ganeshan; Esteban N Abot; Jianfeng Zhang; Keith Limbach; Yupin Charoenvit; Denise L Doolan; De-Chu C Tang; Thomas L Richie
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

6.  Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria.

Authors:  Chandy C John; Ann M Moormann; Peter O Sumba; Ayub V Ofulla; Daniel C Pregibon; James W Kazura
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines administered in single and multiple doses in rats.

Authors:  Qigui Li; Michael P Kozar; Todd W Shearer; Lisa H Xie; Ai J Lin; Kirsten S Smith; Yuanzheng Si; Lalaine Anova; Jing Zhang; Wilbur K Milhous; Donald R Skillman
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

8.  Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine.

Authors:  Ruth D Ellis; Michael P Fay; Issaka Sagara; Alassane Dicko; Kazutoyo Miura; Merepen A Guindo; Aldiouma Guindo; Mahamadou S Sissoko; Ogobara K Doumbo; Dapa Diallo
Journal:  Malar J       Date:  2011-01-19       Impact factor: 2.979

9.  The role of animal models for research on severe malaria.

Authors:  Alister G Craig; Georges E Grau; Chris Janse; James W Kazura; Dan Milner; John W Barnwell; Gareth Turner; Jean Langhorne
Journal:  PLoS Pathog       Date:  2012-02-02       Impact factor: 6.823

10.  Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children.

Authors:  Mark R Withers; Denise McKinney; Bernhards R Ogutu; John N Waitumbi; Jessica B Milman; Odika J Apollo; Otieno G Allen; Kathryn Tucker; Lorraine A Soisson; Carter Diggs; Amanda Leach; Janet Wittes; Filip Dubovsky; V Ann Stewart; Shon A Remich; Joe Cohen; W Ripley Ballou; Carolyn A Holland; Jeffrey A Lyon; Evelina Angov; José A Stoute; Samuel K Martin; D Gray Heppner
Journal:  PLoS Clin Trials       Date:  2006-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.